|
|
Fate Therapeutics Inc (FATE) |
|
Price: $1.8400
$-0.08 
-4.167%
|
| Day's High:
| $1.9
| Week Perf:
| -12.38 %
|
| Day's Low: |
$ 1.76 |
30 Day Perf: |
-34.52 % |
| Volume (M): |
1,815 |
52 Wk High: |
$ 23.96 |
| Volume (M$): |
$ 3,339 |
52 Wk Avg: |
$8.22 |
| Open: |
$1.90 |
52 Wk Low: |
$1.76 |
|
|
| Market Capitalization (Millions $) |
181 |
| Shares
Outstanding (Millions) |
98 |
| Employees |
208 |
| Revenues (TTM) (Millions $) |
119 |
| Net Income (TTM) (Millions $) |
-212 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
21 |
Fate Therapeutics Inc
Fate Therapeutics Inc is a biopharmaceutical company that develops advanced cellular therapies that can replace or repair damaged cells in people suffering from severe diseases.
The company is based in San Diego, California, and was founded in 2007.
The company's innovative approach to therapy involves taking cells from a patient's body, engineering them to become specific types of cells, and then reintroducing them into the patient's body, where they can replace or repair damaged cells.
This approach offers a potential solution to many severe diseases, including cancer, genetic disorders, and autoimmune diseases.
Fate Therapeutics Inc's main product is FT516, a treatment designed to replace natural killer cells that work to identify and destroy cancer cells in the body with healthy cells produced outside the body.
They also have other products in development, including FT500, a cancer-killing cell therapy, and FT819, a CAR T-cell therapy for B-cell malignancies.
The company has a strong focus on research and development, and they have partnerships with many leading medical and academic institutions worldwide.
They have also established a strong intellectual property portfolio, which includes over 300 patents and patent applications in the field of cellular therapy.
In summary, Fate Therapeutics Inc is a cutting-edge biopharmaceutical company that develops advanced cellular therapies that can provide a potential cure for many severe diseases.
They have a strong focus on research, development, and intellectual property, making them a leader in the field of cellular therapy.
Company Address: 12278 Scripps Summit Drive San Diego 92131 CA
Company Phone Number: 875-1800 Stock Exchange / Ticker: NASDAQ FATE
| FATE is expected to report next financial results on November 02, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Opthea Limited
Opthea Limited, a leading player in the biotechnology and pharmaceutical industry, has encountered significant setbacks in its financial performance during the fourth quarter of 2023. With a net loss per share of $-0.32, compared to $-14.15 in the previous year, and a declining year-to-date performance of -63.29%, the company's prospects appear bearish. This article delves into the financial struggles of Opthea Limited, highlighting its declining revenue and increased net shortfall, as well as the negative market sentiment surrounding its shares.
Revenue Growth and Operative Earnings:
Although Opthea Limited witnessed a strong revenue growth of 57.996%, generating $0.11 million in the fourth quarter of 2023 compared to $0.07 million in the same quarter the previous year, this positive aspect does not overshadow the overall financial challenges the company faces. The revenue influx was not sufficient to mitigate the increased net shortfall, which reached $-142.521 million for the fourth quarter of 2023, exceeding the $-45.344 million shortfall of the previous year.
|
|
Pharmacyte Biotech Inc
Pharmacyte Biotech Inc: Analyzing Changes in Company Performance
The stockholders of Pharmacyte Biotech Inc were taken by surprise during the May to July 31, 2023 reporting cycle, as unforeseen changes occurred within the business. These changes were primarily reflected in the company's operating loss, which amounted to $-2.075326 million during the aforementioned period. For investors, monitoring this operating loss was crucial in assessing the company's performance.
To better understand the recent fiscal period results, it is important to analyze the preceding quarter. The operating loss in the first quarter of 2023 was $-1.680608 million, indicating a slight improvement compared to the subsequent period. It is worth noting that businesses often experience fluctuating performance, especially when trying to stimulate lucrative revenue streams. The May to July 31, 2023 period was one such instance where shortfalls extended to $-3.183 million.
|
|
Organicell Regenerative Medicine Inc
Organicell Regenerative Medicine Inc Reaches Break-Even in Q3 2023
During the third quarter of 2023, Organicell Regenerative Medicine Inc reached a break-even point of $0.00 per share, compared to the same period last year and the preceding reporting period. This achievement indicates the company's ability to generate revenue to cover its expenses.
However, the company experienced a significant decline in revenue, which crumbled by -28.749% to $1.22 million from $1.71 million during the comparable reporting period a year ago. On the positive side, there was a sequential revenue surge of 44.373% from $0.85 million. This indicates that, while the year-over-year comparison may seem negative, the company has seen substantial growth compared to the previous quarter.
Organicell Regenerative Medicine Inc reported a net shortfall of $-1.618 million in the third quarter of 2023, which is an improvement from a deficit of $-2.727 million in the same reporting period a year ago. This reduction in the net shortfall indicates that the company has managed to control its expenses better, leading to a smaller financial deficit.
|
|
Champions Oncology Inc
Champions Oncology Inc, a company listed on the NASDAQ, has experienced some fluctuations in its stock performance recently. In the preceding month, the stock declined by -3.59%, indicating a slight decrease in investor confidence. However, when considering the overall trend, the stock is still showing a significant increase of 52.04% in 2023.
Currently, Champions Oncology Inc's stock is trading on the NASDAQ at a level that is 15.3% above its 52-week average. This suggests that investors have generally been optimistic about the company's prospects, as the stock is trading at a higher price than what has been seen over the past year.
However, the company's financial performance in the first quarter of 2024 has been less than desirable. Lower turnover has resulted in dwindling revenue, which has further exacerbated an increased shortfall. The company experienced a net shortfall of $-0.19 per share, a significant decline compared to the previous reporting period where the bottom line was also $-0.19 per share.
|
|
Pluri Inc
Pluri Inc, a biotechnology and pharmaceutical company, has recently witnessed a decline in its shares and reported disappointing financial results for the fiscal year closing June 30, 2023. This article will analyze the implications of these results and examine the potential impact on the company in the future.
Decreasing Share Performance:
Over the past week, Pluri Inc's shares experienced a decline of -6.25%, reaching their 52-week low. When considering the year to date performance, the shares have suffered a significant decrease of -41.16%. These figures signal a bearish sentiment among investors and raise concerns about the future prospects of the company.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.16 $ |
| Revenues (TTM) |
1.21 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.48 $
|
| Book Value |
4.45 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.16 $
|
| Revenues (TTM) |
1.21 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.48 $
|
| Book Value |
4.45 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
